Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$5.8MCash on Hand
22.7mo Cash Runway
Follow XBIO by emailGet an email when XBIO reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about XBIO, unsubscribe in one click. Privacy
📣 What XBIO Says Is Next
first quarter of 2027 · “The Proposed Transaction is expected to close in the first quarter of 2027, subject to approval by Xenetic stockholders, the shares of Xenetic common stock issuable in the Proposed Transaction having been approved for listing on Nasdaq, the effectiveness of a resale registration statement on Form S-1 to be filed with the U.S. Securities and Exchange Commission (“SEC”), and the satisfaction or waiver of other customary closing conditions.”
Company press release, Nov 13, 2026 · SEC filing
Q2 2028 · “Lead program targeting potential EU market launch in Q2 2028”
Company press release, Sep 23, 2026 · SEC filing
fourth quarter of 2026 · “The Proposed Transaction is expected to close in the fourth quarter of 2026, subject to approval by Xenetic stockholders, the shares of Xenetic common stock issuable in the Proposed Transaction having been approved for listing on Nasdaq, the effectiveness of a resale registration statement on Form S-1 to be filed with the U.S. Securities and Exchange Commission (“SEC”), and the satisfaction or waiver of other customary closing conditions.”
Company press release, Sep 16, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 13, 2026 ·
Earnings Reported Q3 2026 results: royalty revenue fell about 29% to $0.7 million, R&D fell 31% to $0.5 million, G&A rose 138% to $1.9 million on Proposed Transaction costs, net loss was $1.7 million ($0.72 per share), and cash was $5.8 million. Form 8-K · SEC filing · Press release
Nov 12, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Sep 23, 2026 ·
Deal Xenetic furnished an updated September 2026 investor presentation tied to its pending share exchange with Santersus AG, which shareholders must approve. The presentation outlines combined-company plans, including NucleoCapture and DNase programs. Form 8-K · SEC filing · Press release
Sep 16, 2026 ·
Deal Xenetic agreed to acquire all share capital of Santersus AG in an all-stock deal, with Santersus holders expected to own about 85% of the combined company and the company renamed Santersus Bio, Inc. (SNTS). Closing requires Xenetic stockholder approval. Form 8-K · SEC filing · Press release
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
XBIO holds $5.8M in cash and short-term investments (as of Sep 30, 2026) and burns about $768,810/quarter from operations,
an estimated runway of 22.7 months at that rate (BioRadar estimate, not company guidance).
Share count 2,343,181 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full XBIO picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for XBIO and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.